NCT03642964View on ClinicalTrials.gov

A Study in Patients With Major Depressive Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

CTC-501

pramipexole IR, given with ondansetron

Trial Locations (1)

90806

Collaborative Neuroscience Network, Long Beach

Sponsors
All Listed Sponsors
lead

Chase Therapeutics Corporation

INDUSTRY

NCT03642964 - A Study in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter